MedTrace Logo

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)

NCT01324466 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 847

Last updated 2013-05-23

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).

Conditions

  • Recurrent Herpes Labialis

Interventions

DRUG

NB-001

Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days

DRUG

Vehicle

Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days

Sponsors & Collaborators

  • NanoBio Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324466 on ClinicalTrials.gov